SWOG Institutional Grant
SWOG 机构补助金
基本信息
- 批准号:7178192
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-06-16 至 2009-12-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAcuteAcute leukemiaAddressAdmission activityAdultAdverse effectsAdverse eventAffectAgreementAmbulatory Care FacilitiesAmerican Cancer SocietyAnaplastic astrocytomaAnimal ModelAnniversaryAnsamycin Antineoplastic AntibioticAntigen-Presenting CellsApoptosisArchivesAreaArsenic TrioxideArtsAwardB-Cell LymphomasBMS-188797BackBaptist ChurchBasic ScienceBedsBehaviorBehavioralBevacizumab/Capecitabine/OxaliplatinBindingBiologyBloodBone DiseasesBortezomibBostonBrain NeoplasmsBreastBreast Cancer TreatmentBudgetsCD4 Positive T LymphocytesCalendarCancer BiologyCancer BurdenCancer CenterCancer ControlCancer Control ResearchCancer Control Research ProgramCancer PatientCancer Prevention InterventionCancer Therapy Evaluation ProgramCantorCapecitabine/IrinotecanCarboplatinCaregiversCaribbean nativesCaribbean regionCaringCase StudyCell CommunicationCell Cycle RegulationCell LineCell TherapyCell physiologyCellsCertificationCessation of lifeCetuximabChargeChemotherapy-Oncologic ProcedureChestCigaretteCisplatinClinicClinicalClinical DataClinical InvestigatorClinical PharmacologyClinical ResearchClinical Research AssociateClinical TreatmentClinical TrialsClosureCognitive TherapyCollaborationsCollectionColorectal CancerCommunicationCommunity Clinical Oncology ProgramComplementary DNAComprehensive Cancer CenterComputer softwareConditionConduct Clinical TrialsConsensusConsultCore FacilityCorrelative StudyCountryCountyCoupledCredentialingCross PresentationCultured CellsCutaneousCutaneous MelanomaCyclin-Dependent KinasesCyclinsCyclophosphamideDNA Microarray ChipDNA Microarray formatDailyDataData CollectionDatabasesDefectDendritic CellsDepositionDepthDevelopmentDexamethasoneDexamethasone/Doxorubicin/VincristineDiscipline of NursingDiseaseDisorder by SiteDisruptionDistressDistrict of ColumbiaDoctor of MedicineDoctor of PhilosophyDocumentationDominant-Negative MutationDoseDoxorubicinDrug Delivery SystemsDrug KineticsDrug resistanceERBB2 geneERCC1 geneEarly DiagnosisEconomicsEducationEducational ActivitiesElderlyElectroporationEligibility DeterminationEmployeeEngineeringEnrollmentEnsureEtiologyEvaluationExcision RepairExerciseFacility Construction Funding CategoryFacultyFanconi&aposs AnemiaFarnesyl Transferase InhibitorFatigueFellowshipFertilityFloridaFlow CytometryFocus GroupsFosteringFundingGastrointestinal Stromal TumorsGefitinibGene ExpressionGeneral PopulationGenesGenomicsGeographyGoalsGrantGranulocyte-Macrophage Colony-Stimulating FactorGroup MeetingsGrowthHealth Insurance Portability and Accountability ActHealth SciencesHealth systemHematologyHemoglobin concentration resultHistone DeacetylaseHistone Deacetylase InhibitorHome environmentHospitalsHousingHumanIfosfamideImageImatinib mesylateImmuneImmune systemImmunityImmunologyImmunotherapyIn VitroIncidenceIndividualIndividual DifferencesInformaticsInformation SystemsInformed ConsentInhibition of ApoptosisInpatientsInstitutionInterleukin-12Interleukin-2InterventionIslandKarenitecinLY294002LaboratoriesLaboratory ResearchLaboratory StudyLasersLeadLeadershipLeukemic CellLimb structureLiquid substanceLocal Area NetworksLocationLungLymphocyteLymphomaMAP Kinase GeneMS-275Malignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of gastrointestinal tractMalignant neoplasm of kidneyMalignant neoplasm of lungMalignant neoplasm of prostateMantle Cell LymphomaMarrowMeasuresMediatingMedicalMedical OncologyMedical centerMelissaMelphalanMembraneMentorshipMetastatic Neoplasm to the LeptomeningesMetastatic Renal Cell CancerMethodsMicroinjectionsMicroscopeMicroscopyMinorityMissionMolecularMolecular ImmunologyMolecular ProfilingMonitorMorbidity - disease rateMulti-Institutional Clinical TrialMultiple MyelomaMusMyelogenousMyeloid LeukemiaMyeloproliferative diseaseN(delta)-acetylornithine, -isomerN-dodecanoylglutamic acid, -isomer, sodium saltNF-kappa BNational Cancer InstituteNeuraxisNeutropenic EnterocolitisNew AgentsNew Approaches to Brain Tumor Therapy ConsortiumNewly DiagnosedNon-Hodgkin&aposs LymphomaNon-Small-Cell Lung CarcinomaNone or Not ApplicableNuclearNumbersNursesNursing ResearchNursing StaffOligonucleotidesOncogenicOncology GroupOutpatientsPainPalliative CarePathologyPathway interactionsPatient CarePatient Care TeamPatient MonitoringPatientsPatternPersonal SatisfactionPersonsPharmaceutical PreparationsPharmacodynamicsPharmacologyPhasePhase I Clinical TrialsPhase I/II TrialPhase II Clinical TrialsPhase III Clinical TrialsPhenotypePhysician ExecutivesPhysiciansPilot ProjectsPlantsPopulationPopulation GrowthPostdoctoral FellowPreclinical TestingPredispositionPreparationPrevalencePreventionPrimary carcinoma of the liver cellsPrincipal InvestigatorPrintingProcessPrognostic FactorProgram Research Project GrantsProgress ReportsProteasome InhibitionProteasome InhibitorProtein OverexpressionProtein-Serine-Threonine KinasesProto-Oncogene Proteins c-aktProtocol ComplianceProtocols documentationPsychological FactorsPsychological adjustmentPublicationsPuerto RicoPurposeQuality of lifeRRM1 geneRandomized Controlled Clinical TrialsRangeRateRecording of previous eventsRecruitment ActivityRecurrenceRefractoryRegistered nurseRegulationRelapseRenal carcinomaReportingResearchResearch ActivityResearch DesignResearch Ethics CommitteesResearch InfrastructureResearch InstituteResearch PersonnelResearch Project GrantsResearch SubjectsResectedResistanceResourcesRestReview LiteratureRifabutinRiskRoleSamplingScheduleScienceScientistScreening for cancerScreening procedureSecondary toServicesSeveritiesSex FunctioningShared Resource Cancer CenterSiteSlideSmall Inducible Cytokine A3SocietiesSolidSolid NeoplasmSourceSouth AmericaSouthwest Oncology GroupSpecialistSpecimenStagingStandards of Weights and MeasuresStromal CellsSupport of ResearchSymptomsSystemT-Cell ActivationT-Cell LymphomaT-LymphocyteTaxane CompoundTaxesTechniquesTeleconferencesTestingThalidomideTherapeuticTherapeutic StudiesTherapy Clinical TrialsTimeTipifarnibTissuesTopoisomeraseTopoisomerase InhibitorsTopoisomerase-II InhibitorToxic effectTrainingTraining and EducationTransgenic OrganismsTranslatingTranslational ResearchTranslationsTransplantationTravelTreatment ProtocolsTumor AntigensTyrosineUSA GeorgiaUnderserved PopulationUnited StatesUnited States National Institutes of HealthUniversitiesUpdateUrogenital CancerValproic AcidVascular Endothelial Growth FactorsVisionVisitWeekWestern Asia GeorgiaWomanWorkWritingZD1839 (IRESSA)Zarnestraalpha-difluoromethyl-DOPA, -isomeralpha-methylornithine dihydrochloride, -isomeranticancer researchbasebevacizumabcancer carecancer immunotherapycancer preventioncancer therapycell growthchemotherapychronic leukemiacognitive functioncohortcomputer scienceconceptcytokinedaltondata managementdaydesigndigitaldocetaxelexperiencefallsfarnesylationfollow-upfootgastrointestinalgemcitabinegene repairgene therapyhuman FRAP1 proteinhuman RRM1 proteinhuman TOP1 proteinhuman prostaglandin D2 receptorhuman tissueimprovedin vivoinhibitor/antagonistinnovationinsightinterdisciplinary approachinterestinvestigator trainingleukemialiver biopsylorismTOR InhibitormTOR inhibitionmalignant breast neoplasmmedical schoolsmedical specialtiesmelanomamembermetastatic colorectalmolecular dynamicsmolecular imagingmolecular oncologymouse modelneoplastic cellneuro-oncologynovelnovel therapeuticsoncologyoutreachoxaliplatinpatient safetypre-clinicalpreclinical studypreventprogesterone 11-hemisuccinate-(2-iodohistamine)programsprotein farnesyltransferaseprotocol developmentpsychologicpsychosocialquality assuranceresearch facilityresponsesarcomasmall moleculestress managementsymptom managementtaxanetemozolomidetooltool developmenttranslational studytumortumor growthtumorigenesisvector
项目摘要
DESCRIPTION (provided by applicant):
The H. Lee Moffitt Cancer Center and Research Institute (HLMCC), founded by the Florida State legislature in 1981, is dedicated to the prevention and cure of cancer. Situated in West Central Florida, it is ideally situated to translate novel scientific discoveries into state-of-the-science clinical trials. Commensurate with the unprecidented population growth in the state of Florida, the HLMCC presently ranks third in the country in numbers of ambulatory cancer patient visits. It is the only single-site National Cancer Institute-designated comprehensive cancer center in the state of Florida, a recognition it received in 2001 and receives patient referrals from entire Southeast of the United States, in addition to Puerto Rico and Central and South America. In 2005 the HLMCC investigators overwhelmingly decided to transfer co-operative group participation, from the Eastern Cooperative Group to the Southwest Oncology Group (SWOG): this decision was based on geography, and the recruitment of investigators with deep experience in SWOG clinical research activity. As part of the centers' mission to provide total cancer care, Moffitt has developed an extensive affiliate network throughout the states of Florida and Georgia, in addition to the island of Puerto Rico involving twelve institution and over 200 credentialed investigators. This affiliate network will be an integral part of accrual to SWOG trials, and the Moffitt SWOG office will work closely with the HLMCC affiliate office to guide the ongoing credentially, monitoring and education of staff. Key investigators have been identified in each of the disease related tumor programs at the HLMCC, with experience in the design, and writing of investigator-initiated clinical trials, many of whom have NCI grant funding: these investigators will provide the leadership and of the timely activation and accrual of SWOG trials within HLMCC and throughout its' affiliate network, in addition to providing active participation in the biannual SWOG meetings. Thus, through robust participation in the active design and accrual to SWOG cooperative trials, we believe that the HLMCC will advance its goal of providing total cancer care to the Southeast United States, and continue to pursue its' stated mission of curing and preventing cancer as a cause of illness and death.
描述(由申请人提供):
李·莫菲特(H.它位于佛罗里达州西部的西部,理想情况下,将新颖的科学发现转化为最先进的临床试验。与佛罗里达州未经证实的人口增长相称,HLMCC目前在该国的卧床癌患者就诊中排名第三。它是佛罗里达州唯一的单位国家癌症研究所指定的综合癌症中心,它于2001年获得认可,除了波多黎各和中部和南美外,还从美国东南部获得了患者的转诊。 2005年,HLMCC研究人员以压倒性的方式决定将合作团体参与从东部合作集团转移到西南肿瘤学小组(SWOG):这一决定是基于地理位置的,并招募了在SWOG临床研究活动中经验丰富的研究人员。作为提供全面癌症护理的中心任务的一部分,莫菲特(Moffitt)除了涉及十二家机构和200多名证书调查员的波多黎各岛外,还在整个佛罗里达州和佐治亚州建立了广泛的会员网络。该会员网络将是SWOG试验不可或缺的一部分,Moffitt Swog办公室将与HLMCC会员办公室紧密合作,以指导正在进行的资格,对员工的监控和教育。在HLMCC的每个与疾病相关的肿瘤计划中都确定了主要的研究者,并具有设计经验,并撰写了研究者发起的临床试验,其中许多人都有NCI赠款资金:这些研究者将提供HLMCC及其在整个生物网络中的SWOG试验的领导和及时激活和应计的SWOG,并提供了BIAN的参与。因此,通过强大的参与积极的设计并累积了合作试验,我们认为HLMCC将促进其为向美国东南部提供全面癌症护理的目标,并继续追求其既定的康复和预防癌症的使命,以此作为疾病和死亡的原因。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VERNON K. SONDAK其他文献
VERNON K. SONDAK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VERNON K. SONDAK', 18)}}的其他基金
MELANOMA VACCINE--TYROSINASE/GP100 W/ MONTANIDE ISA51 OR GM CSF
黑色素瘤疫苗 - 酪氨酸酶/GP100 W/ Montanide ISA51 或 GM CSF
- 批准号:
6303499 - 财政年份:1999
- 资助金额:
-- - 项目类别:
ADOPTIVE CELL THERAPY OF SOFT TISSUE SARCOMAS USING AUTOLOGOUS TUMOR VACCINATION
使用自体肿瘤疫苗接种软组织肉瘤的过继细胞疗法
- 批准号:
6297203 - 财政年份:1998
- 资助金额:
-- - 项目类别:
ADOPTIVE CELL THERAPY OF SOFT TISSUE SARCOMAS USING AUTOLOGOUS TUMOR VACCINATION
使用自体肿瘤疫苗接种软组织肉瘤的过继细胞疗法
- 批准号:
6113552 - 财政年份:1998
- 资助金额:
-- - 项目类别:
MELANOMA VACCINE--TYROSINASE/GP100 W/ MONTANIDE ISA51 OR GM CSF
黑色素瘤疫苗 - 酪氨酸酶/GP100 W/ Montanide ISA51 或 GM CSF
- 批准号:
6297069 - 财政年份:1998
- 资助金额:
-- - 项目类别:
MELANOMA VACCINE--TYROSINASE/GP100 W/ MONTANIDE ISA51 OR GM CSF
黑色素瘤疫苗 - 酪氨酸酶/GP100 W/ Montanide ISA51 或 GM CSF
- 批准号:
6263712 - 财政年份:1998
- 资助金额:
-- - 项目类别:
ADOPTIVE CELL THERAPY OF SOFT TISSUE SARCOMAS USING AUTOLOGOUS TUMOR VACCINATION
使用自体肿瘤疫苗接种软组织肉瘤的过继细胞疗法
- 批准号:
6274786 - 财政年份:1997
- 资助金额:
-- - 项目类别:
相似国自然基金
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PRL2/KDM2B维持MLL-r急性髓系白血病干细胞功能的机制研究
- 批准号:82300190
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MCL-1液-液相分离颗粒通过抑制NHE1活性调节急性髓系白血病细胞pH稳态和耐药
- 批准号:82300187
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
索拉非尼靶向c-Kit抑制Skp2介导的DNA损伤修复增强阿糖胞苷对t(8;21)急性髓系白血病细胞杀伤及机理研究
- 批准号:82370152
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
时空控释“外泌体背囊”与急性髓系白血病“微环境对话”逆转耐药的功能和机制研究
- 批准号:82372315
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
相似海外基金
Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia
PI3K 抑制预防 B 细胞急性淋巴细胞白血病复发的新用途
- 批准号:
10455633 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia
PI3K 抑制预防 B 细胞急性淋巴细胞白血病复发的新用途
- 批准号:
10289183 - 财政年份:2021
- 资助金额:
-- - 项目类别:
BAK Autoactivation in Hematological Malignancies
血液系统恶性肿瘤中的 BAK 自动激活
- 批准号:
10425322 - 财政年份:2020
- 资助金额:
-- - 项目类别: